Scandinavian Biopharma has expanded the partnership with Emergent Travel Health Inc. to also include the marketing and distribution of Emergent’s oral typhoid vaccine (Ty21a) in Germany.
Emergents oral typhoid vaccine will complement and strengthen Scandinavian Biopharma’s commercial portfolio by leveraging its existing marketing and distribution network in Germany, it states. Due to the travel restrictions during the Covid-19 pandemic the vaccine has not been available in Germany since the first half of 2020. In May 2022 the vaccine was re-launched in the German market.
“We are pleased to expand our commercial footprint in the largest EU market by adding a complementary product to our existing product portfolio. We are really excited to be able to bring back this unique typhoid vaccine to the German market,” says Björn Sjöstrand, CEO of Scandinavian Biopharma.
Photo of Björn Sjöstrand: Scandinavian Biopharma
